GlaxoSmithKline
NEWS
It was a particularly busy week for clinical trial announcements. Let’s take a look.
Read on to learn more about three Series B and C financing rounds in the areas of genetically encoded small molecules, artificial intelligence (AI) and immuno-oncology (IO).
Zai Lab, a China-focused biopharma company that focuses on treatments for cancer and autoimmune diseases, announced positive data for its clinical trial on Zejula (niraparib) for ovarian cancer.
There is some evidence that COVID-19 infection might be linked to an increase in diabetes, particularly Type 1 diabetes, which is an autoimmune disease most commonly diagnosed in children.
The biopharma industry ended February and began March with plenty of clinical trial news. BioSpace shares the highlights.
On Sunday, Boehringer Ingelheim tweeted a message of support for Ukraine, and announced it was standing in solidarity with the embattled Eastern-European country.
The company is conducting analyses to understand safety data that had been gathered prior to the pausing of the three studies, NCT04605159, NCT04980391 and NCT05229068.
Not only is this the first approval for a plant-based vaccine, it’s also the first approval for GSK’s adjuvant.
The new normal may not be particularly new. Although cases appear to be dropping — deaths in the unvaccinated are still high. For that and more COVID-19 stories, continue reading.
JOBS
IN THE PRESS